Value
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.9 |
| P/S | 8.8 |
| EV/EBITDA | 7.4 |
| Fwd P/E | 9.5 |
| PEG | 3.8 |
| Analyst target | 6.0 |
- ▸Forward P/E: 8.6x
- ▸PEG: 2.84
PFE · Why this verdict
Why Pfizer (PFE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Pfizer has beaten EPS estimates in all 4 of the most recent quarters with an average upside surprise of 23.4%, including an exceptional 37.4% beat in Q3 2025, demonstrating consistently strong earnings execution relative to expectations. Catalyst breakdown | EPS beats continue in at least 3 of the next 4 quarters, including the upcoming July 2026 report, with average positive surprise above 10%. | →Stable |
| CounterLarge pharma EPS beats are often driven by cost-cutting and one-time items rather than top-line growth; the weak revenue growth profile suggests the beat streak may be masking underlying business deterioration. | ||
Pfizer converts net income to free cash flow at 165%, with a strong Piotroski F-Score of 7/9, suggesting high earnings quality where reported profits are substantially backed by actual cash generation. Quality breakdown | Free cash flow conversion remains above 120% of net income over the next 4 fiscal quarters. | →Stable |
| CounterHigh FCF conversion in large pharma often includes deferred tax benefits and favorable working capital timing that can reverse; sustained FCF at these levels depends on continued patent-protected product cash flows. | ||
Top-12 products account for 65% of Pfizer's revenue, creating high concentration risk in a portfolio that must rely on continued success of existing blockbusters while revenue growth is weak with earnings growth essentially flat. Bear case | At least 2 new product approvals or major label expansions within 24 months reduce the top-12 concentration ratio below 55%. | →Stable |
| CounterProduct concentration in pharma is a structural feature of patent-driven businesses; having 12 blockbuster products is significantly less risky than depending on 1-2, and the pipeline represents optionality not yet in estimates. | ||
The put/call ratio of 11.4 is among the highest observable levels, indicating that options market participants are buying more than 11 put contracts for every call contract, reflecting extreme downside hedging at current price levels. Key risks | The put/call ratio normalizes below 3.0 within 6 months as the earnings beat streak builds confidence and hedging demand diminishes. | →Stable |
| CounterExtremely elevated put/call ratios can reflect institutional portfolio protection on large existing PFE positions rather than directional bearish bets; it may be a sentiment contrarian indicator that historically precedes rallies. | ||
Pfizer has beaten EPS estimates in all 4 of the most recent quarters with an average upside surprise of 23.4%, including an exceptional 37.4% beat in Q3 2025, demonstrating consistently strong earnings execution relative to expectations.
→StableCatalyst breakdown
- Expectation
- EPS beats continue in at least 3 of the next 4 quarters, including the upcoming July 2026 report, with average positive surprise above 10%.
CounterLarge pharma EPS beats are often driven by cost-cutting and one-time items rather than top-line growth; the weak revenue growth profile suggests the beat streak may be masking underlying business deterioration.
Pfizer converts net income to free cash flow at 165%, with a strong Piotroski F-Score of 7/9, suggesting high earnings quality where reported profits are substantially backed by actual cash generation.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 120% of net income over the next 4 fiscal quarters.
CounterHigh FCF conversion in large pharma often includes deferred tax benefits and favorable working capital timing that can reverse; sustained FCF at these levels depends on continued patent-protected product cash flows.
Top-12 products account for 65% of Pfizer's revenue, creating high concentration risk in a portfolio that must rely on continued success of existing blockbusters while revenue growth is weak with earnings growth essentially flat.
→StableBear case
- Expectation
- At least 2 new product approvals or major label expansions within 24 months reduce the top-12 concentration ratio below 55%.
CounterProduct concentration in pharma is a structural feature of patent-driven businesses; having 12 blockbuster products is significantly less risky than depending on 1-2, and the pipeline represents optionality not yet in estimates.
The put/call ratio of 11.4 is among the highest observable levels, indicating that options market participants are buying more than 11 put contracts for every call contract, reflecting extreme downside hedging at current price levels.
→StableKey risks
- Expectation
- The put/call ratio normalizes below 3.0 within 6 months as the earnings beat streak builds confidence and hedging demand diminishes.
CounterExtremely elevated put/call ratios can reflect institutional portfolio protection on large existing PFE positions rather than directional bearish bets; it may be a sentiment contrarian indicator that historically precedes rallies.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pfizer has beaten earnings estimates in all 4 recent quarters with an average 23.4% upside surprise and converts income to free cash flow at 165%, but near-term growth is weak, the stock trades at analyst targets with only 1% upside, and the put/call ratio of 11.4 signals extreme hedging activity.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.8 |
| ROA | 3.8 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 5.9 |
| Current ratio | 4.7 |
| FCF quality | 10.0 |
| Moat | 6.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 165% FCF/NI
- ▸Rule of 40: 25 (fail)
- ▸Strong Piotroski F-Score: 7/9
Growth
1.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.8 |
| EPS growth | 0.0 |
Momentum
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 1.8 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 4.3 |
- ▸Capitulation risk (RSI 24, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.0%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.6 |
| Analyst rating | 7.5 |
| Price target | 8.0 |
- ▸Analyst upside: 23%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $51,400 (0.000% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.3 |
| quality rank | 1.9 |
| growth rank | 5.0 |
Technical
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.6 |
| support resistance | 9.7 |
| 52w position | 6.8 |
Risk (lower is worse)
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.6 |
| days to cover | 5.8 |
| volatility | 5.9 |
| put call | 10.0 |
| implied vol | 5.5 |
| beta | 10.0 |
| debt equity | 6.7 |
| news risk | 3.0 |
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 5.2 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 707.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:2.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.5<4.5
Warning (0)
none
Reward-to-Risk
2.02
Upside
+10.6%
Downside
5.2%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 29d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Technical at 8.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.5<4.5) reinforce the read. Current asymmetry R:R is 2.02 — supplementary context, not the trigger for this path.
The strongest dimensions are Technical at 8.4, Catalyst at 7.2, and Value at 6.9; the weakest are Growth at 1.9, Momentum at 2.5, and Peer rank at 4.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 2.02 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Beat Streak High Surprise
Trip ifAverage quarterly EPS surprise falls below 5% for 2 consecutive quarters, signaling deterioration from the current 23.4% average.
- P2Fcf Conversion Quality
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive fiscal quarters.
- P3Product Concentration Weak Growth
Trip ifRevenue from the top-12 products rises above 70% of total revenue, indicating greater concentration risk than currently flagged.
- P4Extreme Put Call Hedging
Trip ifPut/call ratio rises above 15, indicating further 30% increase in extreme hedging beyond the already elevated 11.4 level.